Sofosbuvir Treatment

Being approved by FDA on 6th of December 2013, Sofosbuvir treatment is the latest and most advanced chronic Hepatitis C treatment. The drug that contains Sofosbuvir named Sovaldi and developed by Gilead Sciences was one of the most anticipated, if not the most anticipated drug in 2013. In 2014 it is already bound to change the way we treat Hepatitis C because of Sovaldi's key advantages.

sofosbuvir treatment

There are two different treatments with Sofosbuvir. The most important change came for genotype 2 and genotype 3 Hepatitis C, where Sofosbuvir is used as a dual regiment together with ribavirin, antiviral drug that is also used in interferon treatment. The advantages of Sofosbuvir treatment are outstanding:

1. First all-oral treatment. With interferon, patients had to administrate intracutaneous injection, which is both painful for the patient and impractical. In Sofosbuvir treatment a patient needs only to take a pill of Sovaldi (trade name for Sofosbuvir) with little water and that's it.

2. Faster treatment. Hepatitis C treatment with Sofosbuvir takes 12 weeks for genotypes 1, 2 and 4 Hep C. For genotype 3 it takes 24 weeks. This is a great reduction in therapy duration from 24-48 week previous treatment with interferon.

3. No known resistance. The problem with antibiotic and antiviral medicines that have been around for long enough is that the bacteria and viruses learn how to fight them. In the case of Hep C treatment, this is starting to show for interferon, which doesn't work as well as before. However, Sofosbuvir treatment is only beginning and the Hep C virus is not ready for it – therefore there is no resistance against Sofosbuvir. It was also shown that patients that underwent interferon treatment without getting better were helped by Sofosbuvir treatment.

4. No interferon side effects. The previous problem with Hep C treatment with interferon was that interferon produces flu-like side effects. This is natural and expected from interferon, but unwanted in Hep C therapy. Sofosbuvir, on the other side, has no such side effects because Sofosbuvir treatment doesn't use interferon.

The most important thing, however, is the cure rate. The cure rate numbers for interferon are more than 75% for genotype 2 and 3 patients, and less than 50% for most common genotype 1.

Cure rate with Sofosbuvir treatment is an outstanding 89% to 95% for genotype 2, according to the clinical studies. For genotype 3 the cure rate is 61% to 63%. But what makes Sofosbuvir or Sovaldi drug the champion is the cure rate for the most common genotype 1 Hep C – genotype 1 is predominant Hep C with about 70% of all Hep C patients.

89%! This is the cure rate for the most important Hepatitis C genotype, up from less than 50% cure rate with previous interferon treatment.

At the advisory committee hearing, Gilead scientists reported sustained viral clearance at 12 weeks (SVR12) ranging from 89% to 95% for genotype 2 and 61% to 63% for genotype 3. For HCV genotype 1, which accounts for about 70% of all HCV in the United States, sofosbuvir-based triple therapy including pegIFN produced an SVR12 of 89%.

“I think the move away from interferon and toward a high probability of success is remarkably encouraging for all of us…. Suddenly, it's realistic to think we can cure most patients with hepatitis C,” Greg Fitz, MD, president of the American Association for the Study of Liver Diseases.

This is what was the response from one of the leading professionals and experts in not only Hepatitis C, but all liver diseases, according to this Sofosbuvir treatment article.

It is worth mentioning that for Hepatitis C genotype 1 there is a three-drug treatment that includes interferon, ribavirin and Sofosbuvir. The treatment is as such highly successful and with reduced duration, but the addition of interferon in the therapy causes the same side effects and the problem of drug resistance. Also needles have to be used to administer interferon. Nonetheless, the bottom line is that the treatment with the addition of Sofosbuvir is curing Hep C genotype 1 patients like nothing else.

Thanks to Gilead Sciences, the Sovaldi drug containing Sofosbuvir is accessible on the market.

This site is about bring the knowledge of Sofosbuvir treatment and Sofosbuvir itself closed to people. More about the wonder molecule itself, the mechanism of action, Sovaldi drug development and Sovaldi drug costs can be found is Sofosbuvir section.

4 thoughts on “Sofosbuvir Treatment

  • August 14, 2016 at 11:55 pm

    Patients with hepatitis C should be advised to abstain from alcohol use; they should also be advised to use barrier protection during sexual intercourse. Screening high-risk patients and initiating appropriate treatment may decrease the prevalence of cirrhosis and HCC.

  • December 3, 2015 at 2:08 am

    Hi, I just came off a 48 week program of Interferon and Ribavirin treatment for HepC Genotype 3. Wow it was horrible. I was unlucky. The treatment did not work. I still have HepC. I have had HepC for about 35 years. I have really bad scarring (Fibroscan reading of F4), and Sclerosis. Don’t really know how bad that is. However, my blood tests now show my liver is functioning extremely well. Only one bold number in all of my blood tests. My liver is functioning the best it ever has over the last 35 years. To avoid liver cancer sometime in the distant future then I need this new drug. It is not available in Australia because our federal government has not put it on our PBS system (Pharmaceutical Benefit Scheme), where the federal government foots the bill. How do I get this drug in India or even America?


    Ken Healey

    • December 4, 2015 at 8:57 am

      Dear Ken,

      you are completely right about Hepatitis C. While liver function is normal, Hepatitis C virus will eventually manifest in complete liver failure.

      There are two new treatment medicines that have much higher (96-99%) cure rate than interferon (around 50%) and usually don’t produce side effects such as headaches. Their brand names are Sovaldi (400mg sofosbuvir) and the newest is Harvoni (400mg sofosbuvir/90mg ledipasvir). They are readily available in Australia but as you pointed out the Australian federal government doesn’t foot the bill for it. The real problem is the extremely high price of the drugs.

      You can travel to US and obtain Harvoni or Sovaldi there. However, the price of Harvoni is $94,500 per standard 12-week treatment.

      On a more positive note, quite recently the production of generic Harvoni started in India, which brings the prices down to merely $900-1500 per 12-week treatment. You can check out the prices of Harvoni in different countries here. More and more of Hepatitis C patients are going to India to get the generic version of the medicines because of the much reduced price. We working together with Hepatitis C Society in order to create a manual of ‘How to buy generic Harvoni from India’ to help Hepatitis C patients step-by-step. The manual is available for a nominal fee of $14.99 and contains all the information Hepatitis C patients need to buy Harvoni from India. You can get you manual here.

      We hope this answers your question. If you have any other questions, we are here to help you out.

      Kind regards,
      HepC Guides Team

    • April 5, 2016 at 8:31 pm

      HI Ken
      Check out


Leave a Reply

Your email address will not be published. Required fields are marked *